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Abstract
Background: We evaluated the cost-effectiveness of the WINGS project, an intervention to
prevent HIV and other sexually transmitted diseases among urban women at high risk for sexual
acquisition of HIV.
Methods:  We used standard methods of cost-effectiveness analysis. We conducted a
retrospective analysis of the intervention's cost and we used a simplified model of HIV transmission
to estimate the number of HIV infections averted by the intervention. We calculated cost-
effectiveness ratios for the complete intervention and for the condom use skills component of the
intervention.
Results: Under base case assumptions, the intervention prevented an estimated 0.2195 new cases
of HIV at a cost of $215,690 per case of HIV averted. When indirect costs of HIV were excluded
from the analysis, the intervention's cost-effectiveness ratios were $357,690 per case of HIV
averted and $31,851 per quality-adjusted life year (QALY) saved. Under base case assumptions, the
condom use skills component of the intervention prevented an estimated 0.1756 HIV infections
and was cost-saving. When indirect HIV costs were excluded, the cost-effectiveness ratios for the
condom use skills component of the intervention were $97,404 per case of HIV averted and $8,674
per QALY saved.
Conclusions: The WINGS intervention, particularly the two sessions of the intervention which
focussed on condom use skills, could be cost-effective in preventing HIV among women.
Background
HIV infection among women in the United States has in-
creased significantly over the last fifteen years, and recent
estimates suggest that as many as 160,000 adult and ado-
lescent women are living with HIV infection and/or AIDS
[1]. Women accounted for almost one fourth of the new
AIDS cases reported in 1999, and most of these women
were infected with HIV through heterosexual contact.
HIV prevention interventions can reduce risky sexual be-
haviour of women [2], and numerous studies have docu-
mented the effectiveness of various cognitive-behavioural
Published: 11 October 2002
BMC Infectious Diseases 2002, 2:24
Received: 15 May 2002
Accepted: 11 October 2002
This article is available from: http://www.biomedcentral.com/1471-2334/2/24
This article is published in Open Access: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice 
is preserved along with the article's original URL.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/24
Page 2 of 11
(page number not for citation purposes)
group intervention models [3–10]. For example, persons
who participated in a 30-minute condom use skills educa-
tional session in a Los Angeles waiting room were less
likely to return to the sexually transmitted disease (STD)
clinic with a new STD than those who did not participate
in the educational session [11].
Many interventions have been successful in increasing
condom usage by supplementing condom use education
and/or general HIV/AIDS education with training in other
areas, such as negotiation skills (how to suggest condom
use with a new partner), assertiveness skills (how to resist
unwanted sexual advances) and cognitive coping skills
(such as sexual self-control) and by improving self-esteem
[4–6,9,12]. Policy- and decision-makers who plan HIV
prevention programs need information about the cost-ef-
fectiveness of these programs in order to maximize the
benefits of limited HIV prevention resources [7,13].
Here, we evaluated the cost-effectiveness of the Women in
Group Support (WINGS) project, a six-session group-
based intervention that offered training in condom use
skills (using condoms correctly) and in communication
skills (such as talking to sex partners about condom us-
age) for urban heterosexual women at high risk of acquir-
ing HIV and other STDs.
Methods
Intervention content, delivery, and efficacy
The methods of the WINGS intervention trial have been
described previously [10,14,15]. A total of 604 HIV-unin-
fected women at high risk for STD/HIV were recruited
from Baltimore, New York, and Seattle from May 1995
through July 1997. After completing baseline interviews,
the women were randomly assigned to the intervention or
to the control group. The intervention group sessions in-
cluded components on reducing HIV and STD risk identi-
fied by Fisher and Fisher [16], specifically training in the
proper use of male and female condoms and building
skills in communication to sex partners to encourage con-
dom use (Table 1). Participants in the control group at-
tended a 1-hour session on nutrition.
Condom usage by the women in the WINGS intervention
increased substantially, and at least part of this increase
was attributable to intervention's effect on condom use
skills and communication skills [10,15]. A model-based
evaluation of the efficacy of the WINGS intervention [10]
demonstrated that most of the intervention's effect on in-
creasing condom usage was attributable to the condom
use skills component of the intervention.
This analysis focussed on the cost-effectiveness of the in-
tervention. We evaluated the cost-effectiveness of the
complete six-session intervention and the two sessions of
the intervention that addressed condom use skills. For
brevity, we refer to the complete, six-session WINGS inter-
vention as the "complete intervention" and we refer to the
two sessions that addressed condom skills training as the
"condom use skills component" of the intervention. The
condom use skills component was part of (not an alterna-
tive to) the complete intervention. To evaluate the cost-ef-
fectiveness of the condom use skills component of the
intervention, we estimated the increase in condom usage
attributable to the condom use skills component.
We examined cost-effectiveness from the societal perspec-
tive, in which relevant costs and benefits were included in
Table 1: WINGS intervention content
Session title General education activities Condom skills activities Communication skills activities
1. Getting and staying healthy Identifying women's health con-
cerns and community resources 
for women's health
None Introduction to basic elements of 
communication; role plays
2. Straight talk Female anatomy None Barriers to communication; role plays
3. Sexually transmitted diseases and HIV Disease information, including 
long-term consequences of 
STDs in women
Male condom demonstration 
and practice; ways to make 
condom use fun
Ways to introduce condoms to resist-
ant partners
4. Choosing safer sex Contraceptive choices and risk 
reduction
Skill practice in using the 
female condom
Role plays for implementing safer sex
5. Living dangerously: sex, drugs, and 
HIV
Drug use and abuse; signs of 
addiction; treatment resources; 
harm reduction
None "Keeping safe" role plays for risky situ-
ations related to drug and alcohol use
6. Relationships Discussion of risky relationships; 
resources for help and safety 
issues such as shelter programs
None NoneBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/24
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the analysis without regard to who might actually pay the
costs or receive the benefits [17]. We calculated interven-
tion costs for the period during which the intervention
was delivered. Benefits of the intervention (averted HIV
infections) were assumed to accrue in the 6 months fol-
lowing the intervention. The societal cost per HIV infec-
tion included the future medical care costs and indirect
costs such as lost productivity, discounted at 3% annually.
The cost-effectiveness analysis comprised four main steps:
(1) retrospective analysis of the intervention's cost, (2) es-
timation of the number of HIV infections averted by the
intervention, (3) calculation of the cost-effectiveness ra-
tios, and (4) sensitivity analyses to examine how the cost-
effectiveness ratios would change over a range of assump-
tions about cost and effectiveness. We present the meth-
ods to evaluate the cost-effectiveness of the complete
intervention. Except where noted, the methods to evalu-
ate the "condom use skills component" were identical.
Estimating the intervention's cost
Cost estimates (in 1996 dollars) were based primarily on
cost information provided by the WINGS principal inves-
tigators, who estimated the various resources required to
deliver the intervention. We obtained additional informa-
tion from budget proposals of the WINGS project and
from cost estimates of an earlier intervention of similar
duration and intensity [13]. Because women attended ses-
sions in small groups, costs were calculated per group of
six women. Our assessment of intervention costs included
the cost of rent for participant meeting spaces (including
overhead and miscellaneous costs), facilitator wages and
training, senior staff time for quality assurance, recruit-
ment, client costs (incentive payments, child care and
transportation compensation, and meals), and materials
(such as condoms, anatomic models, and information
pamphlets).
The child care compensation, travel compensation, and
incentive payments were assumed to cover all costs (direct
and indirect) borne by the participants, such as travel ex-
penses and foregone time for work or leisure. In calculat-
ing recruitment costs, we assumed that 75% of the total
recruitment costs could be attributed to the randomized
control nature of the study and not to the intervention it-
self.
In assessing the cost of the condom use skills component
of the intervention, we divided each cost item included in
the complete intervention (except recruitment and mate-
rials) by three, as the condom use skills component had
one-third the number of sessions as the complete inter-
vention. Recruitment and materials costs in the condom
use skills component were assumed to be the same as the
complete intervention, since recruitment would still be
necessary regardless of the duration of the intervention
and since most of the materials cost in the complete inter-
vention were attributable to the two sessions of the inter-
vention focussing on condom use skills.
HIV cases averted
The number of HIV infections averted (A) by the interven-
tion was estimated according to Equation 1:
where the intervention is assumed to increase the percent-
age of sexual encounters protected by condoms from b to
i,  is condom effectiveness per act of intercourse, R is
the probability of acquiring HIV in the absence of the in-
tervention, and N is the number of women in the inter-
vention.
This approximation is derived from a model-based evalu-
ation of the benefits of increases in occasional condom us-
age, which suggested that under conditions that prevail in
many at-risk heterosexual populations the relationship
between increased condom usage and HIV risk reduction
is essentially linear [18]. For example, if condoms were
95% effective in preventing HIV transmission, then an in-
crease in condom usage from 0% to 100% would reduce
the risk of acquiring HIV by about 95%. Smaller increases
in condom usage would yield smaller reductions in risk.
Parameter values for equation 1 are summarized in Table
2. Values for b and i were obtained from the structural
equation model estimates in a previous study of the effi-
cacy of the WINGS intervention [10]. Based on these
model estimates (see appendix), we applied the following
base case values for condom usage following the interven-
tion: 53.2% for the control group, 57.7% for the complete
intervention, and 56.8% for the condom use skills com-
ponent.
Based on data from several sources, we assumed 0.019 as
the base case annual probability of acquiring HIV in the
absence of the intervention. Recent studies of high-risk ur-
ban women from several cities in the United States suggest
HIV incidence rates in the range of 0.018 to more than 7
new infections per 100 person-years [19–24], with the
highest rates observed among women who reported ex-
changing sex for money or drugs and women with a recent
history of acquiring other STDs such as syphilis. Of the
women initially recruited for the WINGS trial, about one-
fourth reported trading sex for money or drugs and almost
one-third reported having an STD in the previous year
[14].
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Condom effectiveness (), the reduction in the per-act
probability of HIV transmission when a condom is used,
was set to 95% [25]. We assumed the increase in condom
usage attributable to the intervention would last 6 months
(range: 3 to 9) as the increases in condom usage attribut-
able to the intervention were found to diminish by the six-
month follow-up interviews [10].
The value of R was calculated from the annual probability
of HIV infection (P) and the assumed duration of the in-
tervention in months (D) as follows: R = 1 - (1 - P)D/12.
Thus R represents the base case probability of acquiring
HIV (in the absence of the intervention) during the D
months following the intervention.
Cost-effectiveness ratios
Using standard methods of cost-effectiveness analysis, we
calculated the average cost per HIV case averted as the net
cost of the intervention divided by the estimated number
of HIV infections averted, where net cost refers to the in-
tervention's cost minus the societal costs of HIV averted
by the intervention [26]. Averted HIV costs were calculat-
ed by multiplying the estimated number of averted HIV
cases by the cost per case of HIV.
Our baseline estimate of the societal cost of HIV was
$337,000 per case, which includes the lifetime medical
care costs ($195,000, with future costs discounted at 3%
annually) and indirect costs ($142,000) such as lost eco-
nomic productivity [27,28]. This estimate of the indirect
costs per case of HIV was based on a recent report that in-
direct costs of HIV in England comprised between 45% to
102% of the direct treatment costs of HIV [28]. We used
the midpoint of this range and assumed that indirect costs
would be 73% of the direct medical costs ($195,000 
73% = $142,000). This estimate of the indirect costs is
quite conservative compared to other studies which sug-
gest the indirect costs of HIV exceed the direct medical
care costs [29,30].
We did not calculate the cost per quality-adjusted life year
(QALY) gained when indirect costs of HIV were included
in the cost per case of HIV, because these indirect costs
might be "double counted" if included in the numerator
(as averted HIV costs) and the denominator (as part of the
QALY measure) [31,32]. For completeness, we repeated
the analysis excluding the indirect costs of HIV from the
numerator, focussing solely on the direct medical care
costs ($195,000). The cost per QALY saved was calculated
as the net cost of the intervention (the intervention's cost
minus the direct medical care costs of HIV averted) divid-
ed by the number of QALYs saved. The number of QALYs
saved was calculated by multiplying the estimated
number of averted HIV cases by published estimates of the
number of QALYs saved per HIV case averted [27].
To assess the cost-effectiveness of the complete interven-
tion and the condom use skills component, we compared
these interventions to the alternative of no intervention,
which we assumed would have $0 in program cost and
would not avert any new cases of HIV. For the complete
intervention, we also calculated the incremental cost-ef-
fectiveness ratios, which compare the complete interven-
tion to the condom use skills component. The
Table 2: Behavioural, epidemiological, and cost parameters: Base case values and ranges
Parameter Base case value Range Source
Condom use, without participation in intervention (b) 53.2% - Greenberg et al [10], as 
described in appendix
Condom use, with participation in full intervention (i) 57.7% 55.45% – 59.95% Greenberg et al [10], as 
described in appendix
Condom use, with participation in condom use skills 
component of intervention (i)
56.8% 55% – 58.6% Greenberg et al [10], as 
described in appendix
Annual probability of HIV infection without participation 
in intervention (P)
0.019 0.0095 – 0.029 Various (see text)
Condom effectiveness () 95% 85% – 98% Pinkerton and Abramson [25]
Number of women in intervention (N) 266 - Greenberg et al (2000) [10]
Duration of intervention effect in months (D) 6 3 – 9 Greenberg et al (2000) [10]
Societal cost per case of HIV (includes direct medical 
care costs, lost economic productivity and other indirect 
costs)
$337,000 $169,000 – $506,000 Holtgrave and Pinkerton [27] 
and Mullins et al [28], as 
described in text
Direct medical care costs per case of HIV $195,000 $98,000 – $293,000 Holtgrave and Pinkerton [27]
Number of QALYs saved per HIV infection averted 11.23 9.34 – 13.18 Holtgrave and Pinkerton [27]
Note: Costs are expressed in 1996 US$.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/24
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incremental cost per case averted was calculated as differ-
ence in net cost (the net cost of the complete intervention
minus that of the condom use skills component) divided
by the difference in HIV cases averted (HIV cases averted
by the complete intervention minus the HIV cases averted
by the condom use skills component) [26]. The incremen-
tal cost per QALY saved was calculated in an analogous
manner.
Sensitivity analyses
We conducted univariate and multivariate sensitivity
analyses. In the univariate analysis, we examined how the
estimated cost per case averted changed when we varied
one parameter at a time, holding other parameters at their
base case values. The parameters we varied were the cost
of the intervention, the effectiveness of the intervention
(as measured by condom usage after the intervention),
condom efficacy, the annual probability of acquiring HIV,
the duration of the effectiveness of the intervention, and
the cost per case of HIV.
In the multivariate analysis we varied all of the parameters
listed above simultaneously. Specifically, we chose values
for each parameter under the assumption that these values
were uniformly distributed between their respective lower
and upper bounds. We then estimated the cost per case
averted using these random values. We repeated this pro-
cedure 20,000 times (a "Monte Carlo" simulation [33]) to
obtain a distribution of the estimated cost-effectiveness
ratios.
Ranges (upper and lower bounds) of all of the parameters
(except condom use, condom effectiveness, and the
number of QALYs saved per HIV case averted) were cho-
sen as  50% of the parameter's base case value to allow
for a wide variance in the values we applied in our sensi-
tivity analyses. The selection of ranges for condom usage
among intervention participants is described in the ap-
pendix. An analysis of HIV seroconversion studies indicat-
ed that condom usage decrease the per-act risk of HIV
infection by 90% to 95% [25]. We applied a slightly wider
range (85% to 98%) of possible values for condom effec-
tiveness. The range for the number of QALYs saved per
HIV case averted was obtained from a previously pub-
lished study [27].
Results
The intervention costs are summarized in Table 3. The
complete intervention cost an estimated $456 per partici-
pant, while the condom use skills component cost an es-
timated $193 per participant.
Table 3: Summary of cost estimates of complete WINGS intervention, per cohort of six women
Item Cost Description of cost calculations Source
Facility rent $381 1.5 months at $169 per month (25% usage of $677 per-month room, 
including utilities), multiplied by 1.5 to include miscellaneous costs
survey
Facilitator salary and benefits $660 $16 per hour (including fringe benefits), 20.5 hours per facilitator per 
cohort (6 sessions of 3.4 hours including 0.9 hours prep time per ses-
sion), two facilitators per cohort
survey, budget
Facilitator training $61 1.25 hours per facilitator ($16 per hour) per cohort (20 hours overall 
training, divided by 16 cohorts), multiplied by 1.5 to include indirect 
costs, two facilitators per cohort
survey, budget
Recruitment $208 $176 staff time (hours and wages varied across sites) and $32 supplies 
(flyers, ads, letters)
survey, budget
Incentive payments $649 $18 per participant per session, 6 sessions survey
Client transportation/meals $260 $7.23 per participant per session, 6 sessions survey
Senior staff time for quality 
assurance
$110 $18 per participant Holtgrave and Kelly 
[13]
Course materials $159 includes male and female condom models, condoms, printed materi-
als
survey, advertised 
prices
Child care $252 Half of the women (or, 3 women per session) required 2.5 hours of 
childcare per session, at $5.60 per hour, six sessions
Holtgrave and Kelly 
[13]
Total $2,739
Notes: Costs are expressed in 1996 US$. Based on these estimated costs per cohort of six, the cost of the complete intervention per person was 
$456. The estimated cost of the condom use skills component was $1,158 per cohort of six, or $193 per participant. The described calculations 
might not exactly match the cost column due to rounding. In the source column, "survey" indicates the information was based on survey of WINGS 
principal investigators and "budget" indicates the information was based on budget proposals submitted by WINGS principal investigators.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/24
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Table 4: Selected cost and effectiveness estimates
Indirect HIV costs included Indirect HIV costs excluded
Item estimated Complete 
intervention
Condom use skills component 
of intervention
Complete 
intervention
Condom use skills component of 
intervention
Cost of intervention $121,296 $51,338 $121,296 $51,338
Expected number of HIV cases averted 0.2195 0.1756 0.2195 0.1756
Expected HIV costs averted $73,960 $59,168 $42,796 $34,237
Net cost (intervention costs – HIV 
costs averted)
$47,336 -$7,830 $78,500 $17,101
Average cost per HIV case averted $215,690 cost-saving $357,690 $97,404
Incremental cost per HIV case averted $1,256,831 - $1,398,831 -
Average cost per QALY na na $31,851 $8,674
Incremental cost per QALY na na $124,562 -
Notes: Costs are expressed in 1996 US$. The average cost per case averted (the average cost-effectiveness ratio) compares each option to the 
alternative of no intervention, which has a program cost of $0 and results in 2.54 new HIV infections. The incremental cost-effectiveness ratios 
compare the complete intervention to the option of offering only the condom use skills component. "Cost-saving" indicates that the averted HIV 
costs exceeded the cost of the intervention. We did not calculate cost-effectiveness ratios using QALYs when indirect HIV costs were included in 
the analysis, as the QALY measures to some degree incorporate these indirect costs.
Table 5: Univariate sensitivity analyses: Estimated cost per HIV case averted over a range of parameter values
Indirect HIV costs included Indirect HIV costs excluded
Parameter varied Complete intervention Condom use skills 
component
Complete intervention Condom use skills 
component
Annual probability of acquiring HIV = 0.0095 $771,037 $249,215 $913,037 $391,215
Annual probability of acquiring HIV = 0.029 $24,186 cost-saving $166,186 cost-saving
Condom use = 55.45% (55% for condom use skills 
component)
$768,380 $247,809 $910,380 $389,809
Condom use = 59.95% (58.6% for condom use skills 
component)
$31,460 cost-saving $173,460 cost-saving
Duration of intervention effect (months) = 3 $765,735 $246,410 $907,735 $388,410
Duration of intervention effect (months) = 9 $32,343 cost-saving $174,343 $403
Condom effectiveness = 85% $347,154 $24,957 $489,154 $166,957
Condom effectiveness = 98% $181,482 cost-saving $323,482 $79,307
Intervention cost = $228 ($97 for condom use skills 
component)
cost-saving cost-saving $81,345 cost-saving
Intervention cost = $684 ($290 for condoms use 
skills component)
$492,035 $102,364 $634,035 $244,364
Cost per case of HIV = $169,000 ($98,000 excluding 
indirect costs)
$383,690 $123,404 $454,690 $194,404
Cost per case of HIV = $506,000 ($293,000 exclud-
ing indirect costs)
$46,690 cost-saving $259,690 cost-saving
Note: Costs are expressed in 1996 US$. "Cost-saving" indicates that the averted HIV costs exceeded the cost of the intervention.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/24
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The complete intervention averted an estimated 0.2195
new infections (Table 4) at a cost of $215,690 per case
averted, while the condom use skills component averted
an estimated 0.1756 and was cost-saving. Compared to
the condom use skills component, the incremental cost-
effectiveness ratio of the complete intervention was more
than $1 million per case averted.
When we excluded the indirect costs of HIV, the cost per
case averted was $357,690 for the complete intervention
and $97,404 for the condom use skills component. The
cost per QALY saved was $31,851 for the complete inter-
vention and $8,674 for the condom use skills component.
Sensitivity analyses
In the univariate sensitivity analysis (Table 5), the cost per
case averted for the complete intervention ranged from
cost-saving (a negative cost per case averted) to more than
$750,000. The cost per case averted for the condom use
skills component ranged from cost-saving to almost
$250,000. The results were most sensitive to changes in
the annual probability of acquiring HIV, the effectiveness
of the intervention (as measured by condom use among
intervention participants), the duration of the interven-
tion's effect on condom usage, and the cost of the inter-
vention. When indirect costs of HIV were excluded, the
cost per case averted ranged from $81,345 to more than
$900,000 for the complete intervention and from cost-
saving to almost $400,000 for the condom use skills com-
ponent.
In the multivariate sensitivity analysis (Table 6), the cost
per case averted for the complete intervention ranged
from cost-saving to more than $1.5 million, with a medi-
an value of $302,254. The cost per case averted for the
condom use skills component ranged from cost-saving to
more than $600,000 per case of HIV averted, with a medi-
an value of $13,504. When considering only the direct
medical care costs of HIV, the median cost per case averted
was $444,409 (range: $27,506 to $1.6 million) for the
complete intervention and $150,201 (range: cost-saving
to $783,820) for the condom use skills component.
Discussion
This analysis supports the findings of previous studies that
demonstrate that multi-session behavioural interventions
in group settings can be cost-effective tools in the preven-
tion of HIV [34]. Our analysis indicated that the complete
intervention prevented an estimated 0.2195 new cases of
HIV at a cost of $215,690 per case of HIV averted. The
condom use skills component prevented an estimated
0.1756 HIV infections and was cost-saving.
The cost-effectiveness ratios appear less favourable when
the indirect costs of HIV are not included in the analysis.
When excluding indirect costs of HIV, the cost per case of
HIV averted was $357,690 for the complete intervention
and $97,404 for the condom use skills component. The
cost per QALY saved was $31,851 for the complete inter-
vention and $8,674 for the condom use skills component.
To put these estimates into perspective, a recent review of
HIV prevention interventions in the USA suggested that
an HIV prevention intervention can be considered cost-ef-
fective if the cost per QALY saved is less than $50,000
[34]. The base case estimates of the cost per QALY averted
for the complete intervention and the condom use skills
component fell below this $50,000 threshold.
Although the WINGS intervention (particularly the con-
dom use skills component) appeared to be cost-effective
in the base case analysis, the estimated cost-effectiveness
of the WINGS intervention is less favourable than that of
two other small group HIV prevention programs for at risk
women [13,35]. Furthermore, the incremental cost per
QALY saved ($124,562) exceeded the $50,000 threshold,
suggesting that the additional benefits of the complete in-
tervention (as compared to the condom use skills compo-
Table 6: Multivariate sensitivity analyses: Estimated cost per case of HIV averted when varying all parameters simultaneously
Indirect HIV costs included Indirect HIV costs excluded
Complete intervention Condom use skills component Complete intervention Condom use skills component
Median $302,254 $13,504 $444,409 $150,201
Lower bound cost-saving cost-saving $27,506 cost-saving
Upper bound $1,522,430 $660,175 $1,635,740 $783,820
Note: Costs are expressed in 1996 US$. "Cost-saving" indicates that the averted HIV costs exceeded the cost of the intervention. The lower and 
upper bound values in the multivariate sensitivity analysis represent the 5th and 95th percentiles, respectively, of the cost-effectiveness ratios gener-
ated in the Monte Carlo estimations.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/24
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nent) might not be worth the additional costs of the
complete intervention.
Improving the cost-effectiveness of HIV prevention inter-
ventions
The finding that the condom use skills component was
more cost-effective than the complete intervention is con-
sistent with previous studies demonstrating the effective-
ness of brief STD/HIV counselling sessions for persons at
high risk for HIV and STDs [8,36]. These findings suggest
the possibility that for a given budget, more HIV infec-
tions could be prevented by providing brief interventions
to a larger number of people at risk for HIV rather than
providing more intensive and lengthy interventions to a
smaller number of people at risk for HIV.
Our analysis also illustrated the importance of targeting
the intervention to those at the highest risk for HIV. The
cost-effectiveness ratios improved substantially when we
assumed an annual probability of acquiring HIV of 3%
per year (Table 5), a probability consistent with HIV inci-
dence rates in some populations of high-risk urban wom-
en [19–22].
Reductions in the cost of the intervention would improve
the program's cost-effectiveness (Table 5). The WINGS in-
tervention might be delivered in a more cost-effective
manner in other settings. For example, if incorporated
into existing programs such as drug treatment or into cor-
rections settings, additional recruitment expenses, incen-
tive payments, transportation, meals, and child care
would not be required.
Limitations
Our analysis is subject to at least four main limitations,
the most important of which is the uncertainty in quanti-
fying the effectiveness of the WINGS intervention. Inter-
vention participants showed a significant increase in use
of the female condom as compared to the control group
[15]. Condom usage, as measured by the odds of condom
use (male and female condoms), increased substantially
for women in the intervention and for women in the con-
trol group [10]. Although this increase in condom usage
for women in the intervention was not statistically differ-
ent from the (lesser) increase shown by women in the
control group, the WINGS intervention did increase con-
dom use skills and communication skills, and these im-
proved skills were linked to increases in the probability of
condom usage [10] (see appendix).
A second limitation is that the condom use skills compo-
nent was not actually offered as separate, brief interven-
tion, but was part of the six-session intervention required
of all of the WINGS participants. As a result, we based our
analysis of the effectiveness of the condom use skills com-
ponent and the complete intervention on estimates of the
efficacy of individual components of the intervention sug-
gested by a structural equation model of the complete in-
tervention's efficacy (see appendix). If we incorrectly
attributed some of the effect of the complete intervention
to the condom use skills component, our estimates will
understate the incremental cost-effectiveness of the com-
plete intervention and overstate the average cost-effective-
ness of the condom use skills component. Further,
because the effects of the condom use skills component
may be different when provided alone than when provid-
ed in the context of a longer, multifaceted intervention,
the estimated cost-effectiveness of the condom use skills
component may be biased.
A third limitation is the uncertainty in estimating the
number of HIV infections averted by the increase in con-
dom use. Our simple approximation was based on an ap-
plication [18] of a Bernoulli model of HIV transmission
which found that the relationship between increased con-
dom usage and HIV risk reduction is essentially linear for
most heterosexuals at risk for HIV.
In our simplified model we applied the estimated annual
probability of acquiring HIV among high-risk urban
women. This average annual probability reflects an aver-
age of the various epidemiological and behavioural fac-
tors which affect the annual probability of acquiring HIV,
such as per-act HIV transmission probabilities, number of
sex partners, and HIV prevalence rates in the sex partners.
The annual probability of acquiring HIV was the only key
input required for our model to provide an estimate of the
number of HIV cases averted through an increase in con-
dom usage. Precise values for annual probability of ac-
quiring HIV were difficult to obtain. Our base case
probability of acquiring HIV for the WINGSparticipants
(0.019) was higher than suggested by the incidence rates
reported in some studies of women at high risk for acquir-
ing HIV (0.018 to 1.2 new infections per 100 person-years
[23,24]), but substantially lower than others (3 or more
new infections per 100 person-years [19–22]).
A fourth limitation is that we collected cost information
retrospectively from the WINGS intervention principal in-
vestigators. The cost estimates they provided, however,
were reasonably consistent with the detailed budget pro-
posals they submitted prior to the delivery of the interven-
tion. Furthermore, the estimated cost of the WINGS
intervention ($456 per participant) is consistent with that
of other small-group HIV prevention interventions for
women ($450 per participant in a seven-session interven-
tion [35] and $300 per participant in a five-session inter-
vention [13]).BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/24
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Potential underestimation of cost-effectiveness
Unlike the WINGS intervention, many HIV interventions
have been found to be cost-saving [7,34], which occurs
when the costs of HIV averted by the intervention out-
weighs the cost of implementing the intervention. We
note that the condom skills component of the interven-
tion, however, did appear to be cost-saving when indirect
costs of HIV were included in the analysis. Under many
scenarios explored in the sensitivity analyses the WINGS
intervention and the condom use skills component were
cost-saving.
Furthermore, additional limitations of our analysis may
have caused a substantial underestimation of the cost-ef-
fectiveness of the WINGS intervention. First, our analysis
focussed on the prevention of the acquisition of HIV
among women in the intervention and ignored the possi-
bility of preventing HIV infection among the women's sex
partners. Second, in focussing only on HIV prevention we
ignored other potential benefits of the intervention such
as reductions in STDs and unintended pregnancies.
Third, although the intervention participants reported a
substantial increase in condom usage, we only attributed
a small part of this increase to the effects of the interven-
tion. The increase in condom usage we did attribute to the
intervention was the increase above and beyond the in-
crease in condom usage reported by the control group,
and it is possible that part of the increase in condom usage
by the control group was attributable to participation in
the WINGS trial. For example, measures of condom use
skills were obtained for women in the control group on
several occasions, requiring the women to perform such
tasks as opening the condom package, unrolling the con-
dom, and placing the condom on an anatomical model. If
participation in these tasks contributed to the increase in
Figure 1
Simplified version of structural equation model used to evaluate the effectiveness of the WINGS intervention. The regression
coefficient linking the Treatment or Control Group Status variable and the Odds of Condom Usage is (A*B) + (C*E*F) +
(A*D*F), where A,B,C,D,E, and F were obtained from Greenberg et al., 2000 [10].
Treatment or
Control 
Group
Status
Male and Female
Condom Use
Skills
Peer Group
Communication
Asking to 
Use a 
Condom
Odds of
Condom
Usage
A
C
B
D
E
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condom usage by the women in the control group, then
the actual effectiveness of the WINGS intervention would
be understated in our analysis.
Conclusions
In sum, both the complete intervention and the two-ses-
sion condom use skills component appeared to be at least
moderately cost-effective in preventing HIV among at-risk
urban women, using published cost-effectiveness stand-
ards for HIV prevention interventions. Our analysis indi-
cated that group interventions consisting of two sessions
may be more cost-effective than six sessions and suggested
that, for a given HIV prevention budget, offering brief in-
terventions for a large number of at-risk women may be
more cost-effective in some cases than longer, more inten-
sive and multifaceted interventions for a smaller number
of at-risk women.
Appendix
The efficacy of the WINGS intervention was based on a
previously published evaluation which used a structural
equation model [10]. To estimate b, the probability of
condom use without the intervention, we used the proba-
bility of condom use for the control group. At three
month followup, the (log) odds ratio of protected sex in
the control group was 0.13. Thus, log(b / 1 - b) = .13, or
b / (1 - b) = 1.1388, or b = 0.5324.
To estimate i, the probability of condom use with the in-
tervention, we estimated the increase in condom usage as-
sociated with the intervention. The structural equation
model estimates suggested that the intervention increased
the log (odds) of condom use by 0.1818.
This value was estimated as the appropriate product of the
unstandardized path coefficients connecting the interven-
tion variable to the odds ratio of condom use outcome. A
simplified version of the model at 3 months after the in-
tervention is provided in Figure 1.
Through recursive substitutions [37], it can be shown that
the regression coefficient linking the Treatment or Control
Group Status variable and the Odds of Condom Usage is:
(A*B)+(C*E*F)+(A*D*F), where A,B,C,D,E, and F are all
coefficients to be estimated. Applying the published esti-
mates (Table 3 in Greenberg et al. 2000 [10]) of these co-
efficients yielded an estimated 0.1818 increase in the
(log) odds of condom usage attributable to the interven-
tion. Thus, for the complete intervention, log (i / 1 - i)
= 0.13 + 0.1818, or i / (1 - i) = 1.3659, or i = 0.5773.
Similarly, we calculated the effect of increased condom
use skills by calculating (A*B) + (A*D*F), which yielded
an estimated 0.1436 increase in the log (odds) of condom
usage attributable to the condom use skills component.
Thus, for the condom use skills component, log (i / 1 -
i) = 0.13 + 0.1436, or i / (1 - i) = 1.3147, or i = 0.5680.
In sum, the estimated probability of condom usage for a
given act of sexual intercourse is 53.2% without the inter-
vention, 57.7% for the complete intervention and 56.8%
for the condom use skills component. Using these base-
line probabilities, condom usage is increased by 4.5 per-
centage points (in absolute terms) among women in the
complete intervention, of which 3.6 percentage points
could be attributed to the condom use skills component.
To generate ranges (to be used in the sensitivity analysis)
for the estimated condom usage among intervention par-
ticipants, we varied these increases by  50%.
Competing interests
None declared.
Authors' contributions
HWC conducted the cost and cost-effectiveness analyses
and drafted the manuscript. JBG initiated the study and
contributed to the cost and cost-effectiveness analyses.
MH contributed to the cost-effectiveness analysis and
drafted the appendix. All authors contributed to the writ-
ing and reviewing of the manuscript and have read and
approved the final version.
Acknowledgements
We thank the following WINGS principal investigators for their assistance 
in our cost analysis: David Celentano, ScD, The Johns Hopkins University; 
Ann Downer, EdD, and Virginia Gonzales, EdD, University of Washington, 
Seattle; and Nancy Van Devanter, DrPH, Columbia University. We also 
thank Kathleen Irwin, MD, Centers for Disease Control and Prevention, for 
helpful comments and suggestions.
References
1. Centers for Disease Control and Prevention: HIV/AIDS among
US women: Minority and young women at continuing risk. At-
lanta: Centers for Disease Control and Prevention 2000
2. Exner TM, Seal DW, Ehrhardt AA: A review of HIV interventions
for at-risk women. AIDS Behav 1997, 1:93-124
3. Kelly JA, St Lawrence JS, Hood HV, Brasfield TL: Behavioral inter-
vention to reduce AIDS risk activities. J Consult Clin Psychol 1989,
57:60-67
4. Hobfoll SE, Jackson AP, Lavin J, Britton PJ, Shepherd JB: Reducing in-
ner-city women's AIDS risk activities: a study of single, preg-
nant women. Health Psychol 1994, 13:397-403
5. Kelly JA, Murphy DA, Washington CD, Wilson TS, Koob JJ, Davis DR,
et al: The effects of HIV/AIDS intervention groups for high-
risk women in urban clinics. Am J Public Health 1994, 84:1918-
1922
6. DiClemente RJ, Wingood GM: A randomized controlled trial of
an HIV sexual risk-reduction intervention for young African-
American women. JAMA 1995, 274:1271-1276
7. Holtgrave DR, Qualls NL, Curran JW, Valdiserri RO, Guinan ME, Par-
ra WC: An overview of the effectiveness and efficiency of HIV
preventionprograms. Public Health Rep 1995, 110:134-146
8. Branson BM, Peterman TA, Cannon RO, Ransom R, Zaidi AA: Group
counseling to prevent sexually transmitted disease and HIV:
a randomized controlled trial. Sex Transm Dis 1998, 25:553-560
9. Celentano DD, Dilorio C, Hartwell T, Kelly J, Magana R, Maibach E,
et al: The NIMH multisite HIV prevention trial: Reducing HIV
sexual risk behavior. Science 1998, 280:1889-1894
10. Greenberg J, Hennessy M, MacGowan R, Celentano D, Gonzales V,
Van Devanter N, et al: Modeling intervention efficacy for high-BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/24
Page 11 of 11
(page number not for citation purposes)
risk women – The WINGS Project.  Eval Health Prof 2000,
23:123-148
11. Cohen D, Dent C, MacKinnon D: Condom skills education and
sexually transmitted disease reinfection.  J Sex Res 1991,
28:139-144
12. Cohen DA, Mackinnon DP, Dent C, Mason HR, Sullivan E: Group
counselling at STD clinics to promote use of condoms. Public
Health Rep 1992, 107:727-731
13. Holtgrave DR, Kelly JA: Preventing HIV/AIDS among high-risk
urban women: the cost-effectiveness of a behavioral group
intervention. Am J Public Health 1996, 86:1442-1445
14. Greenberg J, Lifshay J, Van Devanter N, Gonzales V, Celentano D:
Preventing HIV infection: The effects of community linkag-
es, time, and money on recruiting and retaining women in in-
tervention groups. J Womens Health 1998, 7:587-596
15. Van Devanter N, Gonzales V, Merzel C, Parikh NS, Celantano D,
Greenberg J: Effect of an STD/HIV behavioral intervention on
women's use of the female condom. Am J Public Health 2002,
92:109-115
16. Fisher JD, Fisher WA: Changing AIDS-risk behavior. Psychol Bull
1992, 111:455-474
17. Farnham PG, Ackerman SP, Haddix AC: Study design. In Prevention
effectiveness: A guide to decision analysis and economic evaluation  (Edited
by: Haddix AC, Teutsch SM, Shaffer PA, Duñet DO) New York, Oxford Uni-
versity Press 1996, 12-26
18. Pinkerton SD, Abramson PR: Occasional condom use and HIV
risk reduction. J Acquir Immune Defic Syndr Hum Retrovirol 1996,
13:456-460
19. Otten MW Jr, Zaidi AA, Peterman TA, Rolfs RT, Witte JJ: High rate
of HIV seroconversion among patients attending urban sex-
ually transmitted disease clinics. AIDS 1994, 8:549-553
20. Edlin BR, Word CO, McCoy CB, Faruque S, Dushku JC, Holmberg
SD:  HIV incidence among young urban street-recruited
crack cocaine smokers.  Natl Conf Hum Retroviruses Relat Infect
(2nd) 1995
21. Onorato IM, Klaskala W, Morgan WM, Withum D: Prevalence, in-
cidence, and risks for HIV-1 infection in female sex workers
in Miami, Florida. J Acquir Immune Defic Syndr Hum Retrovirol 1995,
9:395-400
22. Peterman TA, Zaidi AA, Wroten J: Decreasing prevalence hides
a high HIV incidence: Miami. AIDS 1995, 9:965-970
23. Weinstock H, Sweeney S, Satten GA, Gwinn M: HIV seroincidence
and risk factors among patients repeatedly tested for HIV at-
tending sexually transmitted disease clinics in the United
States, 1991 to 1996. STD clinic HIV seroincidence study
group. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:506-512
24. Chirgwin KD, Feldman J, Dehovitz JA, Minkoff H, Landesman SH: In-
cidence and risk factors for heterosexually acquired HIV in
an inner-city cohort of women: temporal association with
pregnancy. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:295-
299
25. Pinkerton SD, Abramson PR: Effectiveness of condoms in pre-
venting HIV transmission. Soc Sci Med 1997, 44:1303-1312
26. Haddix AC, Shaffer PA: Cost-effectiveness analysis. In Prevention
Effectiveness: A guide to decision analysis and economic evaluation.  (Edited
by: Haddix AC, Teutsch SM, Shaffer PA, Duñet DO) New York, Oxford Uni-
versity Press 1996, 12-26
27. Holtgrave DR, Pinkerton SD: Updates of cost of illness and qual-
ity of life estimates for use in economic evaluations of HIV
prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol
1997, 16:54-62
28. Mullins CD, Whitelaw G, Cooke JL, Beck EJ: Indirect cost of HIV
infection in England. Clin Ther 2000, 22:1333-1345
29. McKay NL, Phillips KM: An economic evaluation of mandatory
premarital testing for HIV. Inquiry 1991, 28:236-248
30. Holtgrave DR, Valdiserri RO, Gerber AR, Hinman AR: Human im-
munodeficiency virus counseling, testing, referral, and part-
ner notification services. A cost-benefit analysis. Arch Intern
Med 1993, 153:1225-1230
31. Prevention effectiveness: A guide to decision analysis and
economic evaluation.  (Edited by: Haddix AC, Teutsch SM, Shaffer PA,
Duñet DO) New York, Oxford University Press 1996, 12-26
32. Cost-effectiveness in health and medicine.  (Edited by: Gold MR,
Siegel JE, Russell LB, Weinstein MC) New York, Oxford University Press
1996
33. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ: Probabil-
istic sensitivity analysis using Monte Carlo simulation. A
practical approach. Med Decis Making 1985, 5:157-177
34. Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG: Us-
ing cost-effectiveness league tables to compare interven-
tions to prevent sexual transmission of HIV.  AIDS 2001,
15:917-928
35. Pinkerton SD, Holtgrave DR, Johnson-Masotti AP, Turk ME, Hackl
KL, DiFranceisco W, et al: Cost-effectiveness of the NIMH mul-
tisite HIV prevention intervention. AIDS Behav 2002, 6:83-96
36. Kamb ML, Fishbein M, Douglas JMJ, Rhodes F, Rogers J, Bolan G, et al:
Efficacy of risk-reduction counseling to prevent human im-
munodeficiency virus and sexually transmitted diseases: a
randomized controlled trial. Project RESPECT Study
Group. JAMA 1998, 280:1161-1167
37. Short L, Hennessy M: Using structural equations to estimate
the effects of behavioral interventions. Struct Equation Model
1994, 1:68-81
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/2/24/prepub
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com